15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
2020 ◽
Vol 83
(6)
◽
pp. AB41
Keyword(s):
2021 ◽
Vol 85
(3)
◽
pp. AB141
2021 ◽
Vol 85
(3)
◽
pp. AB14
Keyword(s):
2017 ◽
Vol 7
(2)
◽
pp. 243-248
◽
Keyword(s):
2018 ◽
Vol 178
(2)
◽
pp. 406-414
◽
2018 ◽
Vol 178
(2)
◽
pp. e168-e168
◽
Keyword(s):